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A 64-year-old university executive was admitted in 1983 to the
University of Vienna Department of Surgery for the removal of
hemorrhoids, He presented with slight generalized edema, and subse-
quently unselective proteinuria (1.4 g/day) was discovered. He was
transferred to the Nephrology Section and a renal biopsy was sent to
the Department of Pathology of the University of Vienna, Allgemeines
Krankenhaus.
Light microscopy with serial paraffin sections revealed an even,
modest thickening of all peripheral capillary loops of the entire glomer-
ular basement membrane. The number of mesangial cells and the
average area of the niesangium were normal; no inflammatory cells
were detected in the glomerular tufts. Bowman's capsule and the
vascular system were inconspicuous; the interstitial space was slightly
edematous. Proximal tubules contained a few resorption droplets,
which contained albumin and immunoglobulins on immunocytochemi-
cal examination. The tubular system appeared normal otherwise. Silver
impregnation of the paraffin sections showed a serrated pattern of the
basement membranes of the peripheral capillary loops that was caused
by spikes extending from the subepithelial glomerular basement mem-
brane. Immunocytochemical analysis disclosed abundant IgG, C3c, and
C5b-9 in a punctate pattern in the basement membrane. Immune
deposits were evenly distributed within the peripheral capillary walls
and were of similar sizes; they formed a regular, discrete pattern. Weak
staining for Clq was detected, but 1gM, IgA, and fibrinogen were
absent. There was no staining in the mesangium for any of these
molecules.
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Electron microscopic examination showed immune deposits in the
lamina rara externa; these deposits were separated by small spikes of
matrix. The deposits, which consisted of finely granular, moderately
electron-dense material, were covered by podocytes that had lost their
discrete foot processes and had the appearance of flat epithelial cells.
Because investigations showed no evidence of infectious or malig-
nant disease, the lesion was classified as primary (idiopathic) membra-
nous nephropathy, stage II (according to the Ehrenreich and Churg
classification [1]). No treatment was given to the patient for the
following 5 years, during which time the unselective proteinuria in-
creased slightly, to 2.8 g/24 hrs. After 5 years, the plasma creatinine
increased from 0.14 to 0.19 mmol/liter (2.1 mg/dl), and mild hyperten-
sion developed (180/95 mm Hg). At this point, triple therapy according
to the schema of Ponticelli was introduced [2]; the treatment was
associated with stabilization of the creatinine levels for another 1.5
years. Thereafter creatinine levels rose unremittingly, and one year ago
the patient reached end-stage renal failure. He has received hemodial-
ysis treatment since then.
Discussion
DR. DONTSCHO KERJASCHKI (Professor of Pathology, Uni-
versity of Vienna, Allgemeines Krankenhaus, Vienna, Austria):
Among the numerous patterns of immune deposit formation in
human glomerular autoimmune diseases, that of membranous
nephropathy is particularly intriguing because it affects all
glomeruli evenly, and the pathomorphologic and immunohisto-
logic features are virtually identical among different patients.
Also, the clinical course is similar in the majority of patients [1,
3—51. The morphologic changes progress from small subepithe-
hal immune deposits in the lamina rara externa of the glomer-
ular basement membrane (GBM) to large, GBM-matrix-encap-
sulated defects in the GBM that might or might not contain
immunoglobulins and complement components, depending on
whether the disease is in an active stage. Approximately 50% of
the patients with membranous nephropathy follow the course
exemplified by today's case presentation, that is, progression to
renal insufficiency over an average of 10 years, regardless of
therapy [6, 71. In many cases, immunosuppressive therapy does
nothing more than retard the development of relapses of the
nephrotic syndrome; it does not appear to interfere with the
disease's pathogenesis, that is, the formation of immune depos-
its, which eventually leads to glomerular damage. It is hoped,
therefore, that determining the molecular mechanisms involved
in formation of the immune deposits and in the subsequent
glomerular damage will enable us to develop specific "hand-
tailored" diagnostic and therapeutic strategies that will improve
the outcome of patients with this disease.
The availability of experimental animal models of membra-
nous nephropathy has enabled researchers to extend our knowl-
edge of this disease far beyond that possible from the study of
Molecular pathogenesis of membranous nephropathy
Principal discussant: DONTSCHO KERJASCHKI
University of Vienna, Vienna, Austria
Editors
JORDAN J. COHEN
JOHN T. HARRINGTON
NICOLAOS E. MADIAS
Managing Editor
CHERYL J. ZUSMAN
State University of New York at Stony Brook
and
Tufts University School of Medicine
Case presentation
1090
Nephrology Forum: Immune deposits in membranous nephropathy 1091
the limited renal tissue obtainable from patients. Heymann
nephritis (HN) closely mimics the morphologic features and
clinical course of the human disease [8}. Heymann nephritis
originally was induced in rats by active immunization with
homogenates of renal cortex in complete Freunds adjuvant. As
the rats develop antibodies against renal antigens, immune
deposits appear in the capillary loops that are indistinguishable
from immune deposits in human membranous nephropathy.
After 6 to 8 weeks, proteinuria develops and persists through-
out the life of the animals. Because the formation of the immune
deposits in this setting relies on active immunization and active
production of rat IgG against an exogenous antigen, this variant
of the experimental disease was named "active" Heymann
nephritis.
A similar morphologic picture and the development of pro-
teinuria within a few days can be achieved by passive transfer
of autologous or heterologous anti-rat renal cortex antibodies
into healthy rats [9, 10]. This variant of the disease was called
"passive" Heymann nephritis because the nephritogenic anti-
bodies are transferred passively into a normal host. Passive
Heymann nephritis is a favorable system for detailed study both
of one form of immune reactant deposition and of the mecha-
nisms responsible for glomerular damage resulting in protein-
uria. The features of the disease develop rapidly; the kidney as
the target organ is able to concentrate even a few micrograms of
specific IgG to form immune deposits within a short time of
injection. The findings obtained in this model are relevant both
for the active form of Heymann nephritis and possibly, at least
in certain cases, for human membranous nephropathy.
In a 1989 Nephrology Forum, Verroust summarized several
kinetic aspects of the formation of immune deposits in Hey-
mann nephritis [11]. I will focus here on recent concepts of
molecular mechanisms of the formation of immune deposits in
Heymann nephritis.
Formation of immune deposits
Introduction and background. In membranous nephropathy,
as in other examples of glomerular autoimmune disease, the
deposition of immunoglobulins in the capillary loops is the
principal source of damage to the filtration barrier. It soon
became apparent that both in Heymann nephritis and in other
glomerular diseases, the immunoglobulins are present in the
form of immune complexes; an intense search for the respon-
sible antigen or antigens therefore has been conducted. In the
case of Heymann nephritis (as for several other immune com-
plex diseases) [12, 13], antibody-antigen complexes originally
were thought to form in the circulation and then to deposit in a
granular pattern in the peripheral capillary loops [14, 15].
However, later evidence demonstrated that the antigen(s) in-
volved in this disease are present within the glomerulus itself
and that immune complexes form "in situ" following fixation of
circulating specific antibody [16, 17]. An understanding of the
mechanisms of immune deposit formation in Heymann nephri-
tis required identification of the glomerular antigen(s) involved
and a determination of their precise localization in normal and
disease states.
Several attempts have been made to identify the pathogenic
antigen(s) involved in Heymann nephritis. One early strategy
was based on subfractionating a crude extract of rat renal
cortex; the pathogenic activity was recovered in a lipoprotein
fraction named FxIA [15]. From this extract a subfraction was
derived named RTEa5, in which the pathogenic potency con-
tained in the extract of the whole-kidney cortex was concen-
trated [15]. Also, RTEa5 was shown to contain lipids and
proteins (or fragments of proteins) but the precise composition
could not be determined because accurate analytic techniques
(for example, SDS-slabgel electrophoresis) were not available
at the time. Both Fx1A and RTEa5 are still widely used for
induction of active Heymann nephritis, and antibodies raised
against these fractions have been useful in the study of passive
Heymann nephritis.
These and several other attempts at purifying the nephrito-
genic molecule(s) were hampered by the heterogenous nature of
the starting material, Fx1A, and by the variability in its com-
position from one preparation to another and from one labora-
tory to another. We now know that the brush-border region of
proximal tubules contains most if not all of the pathogenic
antigenicity, as shown by indirect immunofluorescence using
either circulating antibodies of Fx lA-immunized rats or glomer-
ular eluates [18].
The identification of gp330 as the pathogenic antigen in
Heymann nephritis. The localization of the pathogenic anti-
gen(s) in the proximal tubule brush border led to attempts at
purifying the corresponding molecule(s) from isolated microvil-
lar fractions that could be prepared in high purity by fraction-
ation techniques originally used for the study of various ion and
glucose transporters. One approach used microvillar fractions
as a source for the production of monoclonal antibodies in the
hope that one or more of these antibodies would induce passive
Heymann nephritis. This goal, however, was not fully accom-
plished [19, 20]. In another approach, the glycoproteins of
solubilized microvilli were subfractionated on lectin columns,
and individual glycoprotein batches were used for the induction
of active Heymann nephritis. Lentil lectin-binding glycopro-
teins (indicative of mannose- and fucose-containing sugar side
chains) were active, but those obtained with other lectins were
much less nephritogenic [21].
Concurrently, we started a series of experiments that were
based on the hypothesis that the IgG in glomerular immune
deposits could be used as a specific probe for identifying the
corresponding antigen(s) in lysates of microvillar proteins [22].
Microvillar fractions from proximal tubules were prepared,
radio-iodinated, and lysed in detergent buffer. Then IgG within
glomeruli of rats with Fx1A-induced active Heymann nephritis
was eluted with citrate buffer. When incubated with the lysates
of microvilli, a single glycoprotein with an apparent molecular
size of 330 kD was selectively immunoprecipitated; we named it
gp330 (Fig. 1). Our assessment of the molecular weight of gp330
originally was based on a comparison with the mobility of
molecular weight standards; our estimate has been confirmed
subsequently both by cleavage of gp330 with cyanogen bromide
and addition of the molecular weights of the individual frag-
ments, and, more recently, by amino acid analysis (unpublished
observations).
Subsequent studies demonstrated that gp330 is a major com-
ponent of Fx1A and of RTEa5 [23]. Whether the gp330 mole-
cule was capable of inducing Heymann nephritis by itself
remained to be shown.
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Fig. 1. Gallery of the currently known gp330-related membrane pro-
teins in rat proximal tubule brush border. Immunoprecipitates of
radio-iodinated rat microvillar proteins with: A Anti-gp330 antibodies
raised in rabbit against purified rat gp330. Note that three bands are
immunoprecipitated with apparent molecular weights of 330, 300, and
280 kD; B Monoclonal anti-gp330 IgG, which selectively recognizes the
gp330 band. An identical pattern of immunoprecipitation was obtained
when the glomerular IgG was eluted from rats with active or passive
Heymann nephritis; C A monoclonal anti-maltase (gp300) antibody (a
gift from Dr. B. Sacktor). In contrast to the anti-gp330 or gp280
antibodies, this IgG was able to specifically deplete a lysate of microvilli
of maltase activity; D A rabbit anti-280 kD antibody (obtained from Dr.
Ch. Leung). This antibody, which selectively recognizes the 280 kD
band, is a potent teratogenic agent in rats in the first half of the
pregnancy.
The induction of immune deposits by anti-gp330 antibodies.
Purified gp330, obtained either by column chromatography or
by electroelution from SDS-gels or by immunoaffinity purifica-
tion with monoclonal anti-gp330 antibodies, was used to immu-
nize susceptible rat strains. Within 4 to 6 weeks, glomerular
subepithelial immune deposits were found; these contained
endogenous rat IgG and gp330 antigen [22]. The glomerular IgG
was acid-eluted and was monospecific for gp330, as determined
by immunoprecipitation. These data thus indicate that subepi-
thelial immune deposits similar to those caused by FxIA
preparations can be induced by purified gp330.
When monospecific anti-gp330 antibodies were prepared by
affinity purification on immobilized purified gp330 from rabbit
or sheep anti-rat Fx1A IgG, and were injected intravenously
into rats, subepithelial immune deposits developed within min-
utes in clathrin-coated pits on the "soles" of the podocytes [24]
(Figs. 2 and 3). A major difference remains, however, between
the functional abnormalities associated with these immune
deposits and those associated with deposits induced by anti-
FxIA IgG; proteinuria was much less prominent or even absent
when monospecific anti-gp330 IgG was used. This observation
indicates that at least one factor in addition to gp330 immune
complexes is necessary for the development of "full-blown"
Heymann nephritis with immune deposits and proteinuria.
Antigens other than gp330. When IgG was eluted from
glomeruli with Fx1A-induced active or passive Heymann ne-
phritis, some investigators discovered that, in addition to
gp330, other molecules also were tagged by the antibodies, as
detected either by immunoblotting or immunoprecipitation of
microvillar proteins [25—30]. This finding was interpreted as
meaning that molecules other than gp330 could contribute to the
formation of immune deposits and/or proteinuria. Subsequently
one of these molecules was identified as the enzyme dipeptidyl-
peptidase IV (DPP IV); intravenous injection of monospecific
anti-DPP IV antibodies gave rise to transient glomerular im-
mune deposits and—at least in one laboratory—also caused
proteinuria [11, 3 1—351. To clarify the role of this enzyme, we
mixed monospecific anti-gp330 antibodies with anti-DPP IV
antibodies (obtained from Dr. P. Verroust) raised in a different
species; we then injected the mixture into rats. When followed
separately by immunoelectron microscopy, the two IgGs did
not co-localize in the immune deposits. Similar results were
obtained when anti-gp330 and anti-laminin antibodies were
mixed. These data indicate that neither anti-DPP IV nor anti-
laminin IgG participates in the formation of immune deposits in
passive Heymann nephritis. It is possible, however, that DPP
IV immune complexes assist indirectly in the development of
gp330-dependent immune deposits [11].
To examine the putative multispecificity of the immunoglob-
ulin within immune deposits in Heymann nephritis in a system-
atic way, we recently obtained sheep Fx1A IgG (provided by
Dr. W. G. Couser, and purified by protein G affinity chroma-
tography) and depleted it completely of its anti-gp330 activity
by passing it repeatedly over a cyanogen bromide-Sepharose
column to which purified gp330 was immobilized. When the
monospecific anti-gp330 IgG from the column was injected into
rats, typical subepithelial immune deposits developed, whereas
the anti-gp330 IgG-depleted anti-Fx1A serum failed to bind to
the glomeruli at all time points studied (from 15 minutes to 7
days after injection; Susani M, Exner M, Kerjaschki D, unpub-
lished observations). These experiments clearly indicate that in
passive Heymann nephritis, anti-gp330 antibodies are the only
fraction of IgG in anti-Fx1A serum capable of forming stable
immune deposits, whereas all the other IgG specificities con-
tained in this serum are not able to do so. Corresponding
experiments also were performed previously in active Hey-
mann nephritis [221; isolated rat microvilli were depleted of
gp330 and used for immunization of rats. Under these condi-
tions, no immune deposits were formed, but purified gp330 gave
a positive result.
Several laboratories have confirmed these findings [19, 25,
28, 36—40]. Others, however, have contested the data and have
described other candidate antigens, which apparently are dif-
ferent from gp330, or of which gp330 is only a component, such
as gp600 141]. For example, anti-gp600 IgG subsequently was
found to be multispecific with a major specificity for gp330, but
also for several other high-molecular-weight proteins as re-
solved by gel filtration of FxIA. In active Heymann nephritis,
some investigators have found circulating immune complexes
[42—44], but the direct nephritogenicity of these complexes has
not been convincingly proved [45]. In one particular case, a
molecule was isolated from these immune complexes that
induced immune deposits when used for active immunization of
rats 1461. It is not yet clear whether such antigens in circulating
immune complexes are related to gp300.
Taken together, the available data indicate that gp330 is the
sole antigen present in Fx1A preparations (and presumably also
in RTEa5) capable of forming stable and persistent immune
deposits in the lamina rara externa in passive and presumably
also in active Heymann nephritis. These findings warrant a
closer inspection of the properties of the gp330 molecule with
particular reference to how its molecular structure could relate
to the formation of immune deposits.
Fig. 2. Passive Heymann nephritis, induced by intravenous injection of affinity-purified rabbit anti-gp330 IgG in rat. A Direct immunofluoresence
showing granular deposits in the peripheral capillary loops; the deposits contain the injected rabbit anti-gp330 antibodies. B Immunoelectron
microscopy using immunoperoxidase for the detection of injected rabbit IgG 6 days after intravenous injection of affinity purified rabbit anti-gp330
IgG into a rat. The arrows show immune deposits that contain reaction product indicative of rabbit IgG in typical subepithelial localization in the
lamina rara externa. In many instances the immune deposits can be seen attached to the basal cell membrane of the podocytes rather than between
the slit diaphragms. mvb: multivesicular body. (A X 1500, B x 25,000.)
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Fig. 3. Early stages of passive Heymann nephritis induced by intravenous injection of monospecfic rabbit anti-gp330 IgG. After 15 minutes (A),
1 hour (B), and I day (C), the injected rabbit IgG is found selectively in coated pits (cp) on the "soles" of the foot processes, and forms small
immune deposits (ID). This is precisely the same location at which gp330 was found previously; the initial immune complexes and early events in
the formation of immune deposits thus likely are tightly associated with clathrin-coated membrane areas of the podocyte membrane. Note that not
all coated pits in this region contain anti-gp330 immune complexes (cp' in C), (Magnification x 75,000.)
Fig. 4. The shape of gp330 visualized by rotaiy shadowing. A Frac-
tions of gel filtration column resolving gp330 and gp300 in the presence
of 1% sodium deoxycholate. The fraction indicated by arrowheads was
used for rotary shadowing. B Images of gp330 indicating that gp330
forms aggregates in which globular domains are associated with stalk-
like regions (outlined in the interpretative drawing in the insert, Kain R,
Kerjaschki D, unpublished observations). (B magnification X 201,600.)
Molecular analysis of gp330 immune complex form ation
Molecular characteristics of gp330. When gp330 was purified
by high-resolution gel chromatography under bona fide non-
denaturing conditions (in the presence of deoxycholate) and
then visualized by rotary shadowing, it was found to form
supramolecular aggregates with stalk-like regions and globular
tops (Kain R, Kerjaschki D, unpublished observations) (Fig. 4).
It is currently not known to which topographic region the
pathogenic antibodies bind, and whether this binding could
cause distortions of the molecular shape.
On the extracellular domain, there appear to be several
N-linked sugar chains, although no further detailed information
is available at the moment. The supposition that glycosylation
occurs is based on the binding of lectins specific for mannose-
containing sugar chains (as shown by Con-A binding) and
fucosylation (as shown by binding of lentil lectin) [22]. It should
be noted that gp330 appears to be identical to the molecule
named "brushin," which was discovered in mouse embryos
and teratocarcinoma cells by affinity purification on a Ulex
Europaeus-lectin column, which binds to fucose [47]. By amino
acid sequencing, several putative N-linked glycosylation sites
were discovered recently (Binder S, unpublished observations).
The biologic function of gp330. Several attempts have been
made to elucidate the function of gp330 in normal tissue. For
example, the localization of gp330 in clathrin-coated pits of the
cell membranes suggests that gp330 could be a receptor for
which the ligands are unknown, or a constitutive membrane
protein in coated pits [24, 48]. Recent binding studies of serum
proteins on denatured gp330 have suggested that gp330 is a
receptor for plasminogen, but proof of this claim by the use of
native non-denatured molecules as ligands was not provided
[49]. Other experiments have shown that monoclonal antibodies
specific for gp330 inhibit the attachment of isolated tubular
epithelial cells to matrix-protein-coated dishes [50], and the
authors concluded that gp330 could serve as a matrix receptor.
However, these studies did not exclude the possibility that the
inhibitory effect of anti-gp330 on cell attachment was indirect.
In addition, defined matrix receptor molecules, such as
integrins, show a completely different distribution in the kidney
than that of gp330 [511.
Although amino acid sequence data have revealed that gp330
contains animal lectin-like domains [52] as well as LDL-recep-
tor-like cystine-rich domains [53], there is no direct proof for
either function. Comparison of all confirmed sequence data
further excludes the possibility that gp330 is identical to the
LDL receptor or the LDL-related molecule (Binder S, Kerjas-
chki D, unpublished data).
Apparently, gp330 is only one member in a larger family of
structurally related glycoproteins that currently includes the
enzyme maltase, which has a molecular weight of 300 kD (and
was therefore named gp300 in our previous studies) (Fig. 1). It
is questionable whether the maltase-splitting activity of this
gp300 molecule is of any biologic relevance in proximal tubules,
because bona fide maltase is never available at this site [54]. It
is currently unexplained why molecules of maltase in the
proximal tubular brush border are associated exclusively with
the membranes of the microvilli, whereas gp330 is present
exclusively in the inter-microvillar microdomain of the cell
membrane, which is clathrin-coated (Fig. 5); also unexplained is
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Fig. 5. Localization of gp330 and clathrin in proximal tubule brush borders using monoclonal anti-gp330 IgG (Figs. A and B) and affinity-purified
rabbit anti-clathrin IgG (Fig. C obtained from Dr. D. Louvard). A Gp33O is localized at the base of the microvilli of proximal tubules and some
granular compartment in the apical region of the proximal tubular cells rather than to the brush border microvilli themselves by indirect
immunofluorescence with monoclonal anti-gp330 IgG. B By immunoelectron microscopy (Lowicryl K4M), gp330 is localized primarily on the
inter-microvillar membrane of proximal tubular brush borders, and on the luminal side of apical vesicles in the proximal tubular epithelial cells.
Only a few gold grains are present on the membranes of the microvilli. C Localization of clathrin, indicating that both the inter-microvillar
microdomain as well as the apical vesicles are endowed with large amounts of clathrin. (A x 576; B and C X 23,040.)
how this polarity is maintained [54, 55]. Another member of the
gp330 familiy is a brush-border glycoprotein with an apparent
molecular weight of 280 kD in SDS gels. This molecule is of
interest because specific antibodies against it cause fetal mal-
formations in rats [56, 57]. Thus despite much effort, the
biologic function of gp330 remains elusive.
"Pathogenic epitopes" on gp330. Several findings indicate
that gp330 expresses "pathogenic epitopes" that form immune
complexes with site-specific antibodies in vivo, thereby leading
to the development of an immune deposit. By contrast, other
antibody-binding sites on (denatured) gp330 are not competent.
One such piece of evidence is derived from the injection into
rats of various monoclonal antibodies, either alone or in com-
bination, that either do not bind to the glomerulus at all or form
small immune deposits that disappear within a few hours [581.
However, some of these monoclonal antibodies strongly bind to
immune deposits when they have been established previously
by injection of, for instance, anti-gp330 antibodies or anti-FxlA
IgG. This finding suggests that more epitopes of gp330 become
exposed as the immune deposits develop (unpublished obser-
vations). Second, when the glomerular IgG, eluted from ani-
mals that had been injected with affinity-purified rabbit anti-
gp330 IgG three days before sacrificing, was subjected to
isoelectric focusing, only a few isoelectric variants of the IgG
were concentrated in the immune deposits, the original affinity-
purified IgG being composed of a wide spectrum of isoelectric
variants 159]. This finding indicates that a small number of
presumably epitope-specific variants are selected and concen-
trated into early immune deposits.
A molecular biologic approach to the identjfication of
"pathogenic epitopes" on gp330. The existence of "pathogenic
epitopes" that are able to initiate immune deposits in vivo has
been established by experiments in which fragments of the
gp330 gene have been identified in cDNA libraries, and the
corresponding fusion proteins have been expressed and probed
for the presence of "pathogenic epitopes" [52]. We have
identified a cDNA-clone, designated as C14, by screening a rat
cDNA library with eluted glomerular IgG from animals with
passive Heymann nephritis for 3 days; these animals were
similar to those used for the initial identification of gp330 (Fig.
6). The amino acid sequence of C14 was determined from the
nucleotide sequence (Fig. 7) and was found to contain four
repeated tryptophan-containing motifs, previously observed in
the ligand-binding domain of various animal lectins, such as
lung surfactant and chicken hepatic lectin. The authenticity of
C14 as a gp330-derived clone was established by either immu-
nizing rats with purified Cl4-3-galactosidase fusion protein, or
by injecting rats with monospecific anti-C14 IgG. In both
instances, the observation of subepithelial immune deposits
(Fig. 8) indicated the presence of at least one "pathogenic
epitope" on C14 [52]. To determine the minimal amino acid
sequence of this "pathogenic epitope," we are currently doing
work to produce deletions in the C14 DNA, thus yielding
smaller fragments of this DNA.
Currently, approximately one-third of the entire amino acid
sequence of gp330 has been elucidated, including one segment
at its N-terminus, which contains multiple cystine-rich motifs of
the LDL receptor [53], in addition to several other fragments of
gp330, which do not show any homology to other proteins. We
expect that several other "pathogenic epitopes" will surface as
more of the amino acid sequence of gp330 becomes known.
Although the number of "pathogenic epitopes" defined by
this strategy is relatively small, it currently is not possible to
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Fig. 6. Identification of a "pathogenic epitope' of gp33O by immuno-
blotting on nitrocellulose transfers. This gp330 epitope is expressed as
a recombinant protein, constructed by fusion of a fragment of the gp330
gene (derived from a lambda-GT1 1 eDNA-library of rat kidney) with E.
coil beta-galactosidase, Lane A: Lysate of E. coli containing a gp330
gene insert and forced to express it as a fusion protein with beta-
galactosidase. In this transfer, which is stained for proteins, a promi-
nent fusion protein (arrowhead) is visible. Lane B: Immunoblot on the
proteins depicted in the preceding lane with monoclonal anti-beta-
galactosidase IgG. The fusion protein and some of its degradation
products are intensively stained. Lane C: Immunoblotting with affinity-
purified anti-gp330 IgG. Note that the fusion protein and the degrada-
tion product are stained. Lane D: Immunoblot with IgG that was eluted
from glomeruli of rats with passive Heymann nephritis. Note that the
fusion protein is selectively stained. This indicates that in this fusion
protein a fragment of gp330 is expressed that serves as an antigenic
target in Heymann nephritis. Lane E: In a control experiment, E. coli
lysate without DNA inserts was immunoblotted with a monoclonal
anti-/3-galactosidase IgG, which selectively stains the native enzyme
with an apparent molecular weight of 160 kD. Lane F: When the same
lysate is immunoblotted with anti-gp330 IgG, no signal is obtained.
predict whether this experimental approach will reveal a com-
prehensive catalogue of all "pathogenic epitopes," because
epitopes dependent on the correct folding of gp330 might not be
present on the /3-galactosidase fusion proteins. It would be
advantageous for us to know the amino acid sequence of all
relevant epitopes of gp330, because this knowledge could set
the stage for novel specific therapies for glomerular immune-
complex diseases similar to those used in other autoimmune
diseases [60, 61].
Mechanisms of the formation of immune deposits
Localization of gp33O in the normal glomerulus and other
tissues. The in-situ formation of immune deposits calls for the
presence of the pathogenic antigen within the glomerulus,
where it meets with specific IgU from the circulation to form an
initial immune complex, which subsequently grows to an im-
mune deposit. Previous experiments using various preparations
of antibodies for the localization of the Heymann nephritis
antigen(s) have suggested that the antigenic targets are present
either in the GBM alone [62) or in the GBM as well as along the
cell membranes of endothelial and epithelial cells in an even
distribution [17]. The availability of monoclonal anti-gp330
antibodies and affinity-purified polyclonal anti-gp330 IgG has
clarified this issue. Found exclusively in glomerular epithelial
cells, gp330 appears in the endoplasmic reticulum and the Golgi
apparatus, indicating that gp330 is a biosynthetic product of
these cells. On the cell surface, gp330 was exclusively associ-
ated with clathrin-coated pits, both on the urinary surface of
glomerular epithelial cells, and most notably also on the
"soles" of the podocytes, that is, the cell membrane that faces
the glomerular basement membrane [24].
In subsequent experiments, gp330 was localized in several
other tissues by immunoelectron microscopy and was exclu-
sively present in clathrin-coated pits, which are endocytic
organelles of cells specialized for the uptake of various ligands
by specific receptor proteins, such as the LDL receptor [631.
For example, in renal proximal tubules, gp330 was found
exclusively in the clathrin-coated inter-microvillar micro-
domains of the brush-border membranes [54] (Fig. 5). The
association between clathrin and gp330 is so strong that it is
maintained even when the brush-border membranes are iso-
lated by biochemical fractionation techniques [55]. Also, gp330
was found in coated pits in the apical membranes of epididymal
epithelial cells, in the rat yolk-sac and type-Il pneumocytes, in
the epithelial cells of ependyma, and in prospective epithelial
cells of early mouse embryos [38, 64, 65].
Formation of immune deposits in coated pits of podocytes.
When polyclonal affinity-purified anti-gp330 IgG was injected
intravenously into normal rats, glomerular subepithelial im-
mune deposits appeared within 10 minutes. These deposits
were found by immunoelectron microscopy exclusively within
the clathrin-coated pits of the glomerular epithelial cells in the
lamina rara externa (Fig. 3). With time, the immune deposits
increased in size but always remained in contact with the
clathrin-coated areas of the podocytes even after several
weeks, presumably because newly formed gp330 is presented
there [59].
Immune deposits firmly adhere to the GBM. The association
of immune deposits with coated pits is intriguing because these
organelles are sites of endocytosis, yet the gp330 immune
complexes were allowed to accumulate there without being
taken up and metabolized by the cell. This phenomenon was
explained by the finding that gp330 immune complexes are
immobilized by attachment to the lamina rara externa of the
GBM as early as 15 minutes after intravenous injection of
anti-gp330 IgG, and the complexes could not be removed by
extraction with detergents, nor by high- and low-salt buffers,
such as those used for the purification of GBM (Fig. 9). By
contrast, the finding that gp330 itself was not detected in the
isolated GBMs indicates that this attachment is specific for
gp330 immune complexes only [59]. The molecular mechanism
accounting for this process, and whether this interaction is
indiscriminate or is selective for individual matrix molecules, is
not known. A similar mechanism conceivably could account for
the formation of stable immune deposits not only in Heymann
nephritis, but also in other glomerular immune complex dis-
eases.
Shedding of gp330 immune complexes from the surface of
podocytes. When cultured glotnerular epithelial cells are ex-
posed to anti-gp330 antibodies to form immune complexes in
their coated pits, these complexes are primarily taken up by the
cells via endocytosis. Apparently, however, the complexes also
are partially shed from the cell surface and released into the
medium [67—69]. Immunohistochemistry studies documented
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Fig. 7. Nucleotide sequence and derived amino acid sequence of the DNA insert of gp330, which was used for production of subepithelial immune
deposits and which bound the eluted glomerular IgG of rats with passive Heymann nephritis. This fusion protein represents the C-terminal portion
of the gp330 molecule. It contains one potential glycosylation site and four repeating tryptophan-containing regions (boxed areas), which are very
similar or identical to conserved domains found in the ligand-binding region of various animal lectins. This insert contains about 280 amino acids.
Fig. 8. Induction of glomerular subepithelial immune deposits by antibodies to the recombinant gp330-/3-galactosidase fusion protein (described
in the preceding figure). A When this IgG is injected intravenously into normal rats, granular immune deposits in the glomerular capillary walls
are observed by direct immunofluorescence. B, C Six weeks after this fusion protein was injected to induce active immunization of rats, granular
immune deposits developed; the deposits contain rat IgG (as visualized by direct immunoperoxidase immunoelectron microscopy). (A >< 500, B
x 26,000, C x 17,000).
patching, capping, and shedding of gp330 immune complexes; lus after injection of anti-gp330 IgG, and this detachment could
these changes resembled similar processes on B-lymphocytes facilitate the anchoring of immune complexes in the GBM. It is
after incubation with anti-immunoglobulin antibodies [67, 68]. remarkable that chiorpromazine, which is known to interfere
A similar detachment process also could occur in the glomeru- with rearrangement of cell surface molecules by influencing the
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Fig. 9. Gp330 immune complexes are rapidly immobilized in the glomerular basement membrane. Anti-gp330 IgG was injected intravenously into
rats, and the glomerular basement membranes were isolated by extraction with detergents. Both gp330 (small gold particles) and the injected IgG
(large particles) were localized simultaneously by immunoelectron microscopy. At 15 minutes (A) and, more pronounced, at 3 days after injection
(B-F), both components of the immune deposits stick firmly to the lamina rara externa, even when the cells have been extracted. (A X 83,300; B
x 117,600; C and D x 83,300; F x 93,100.)
cytoskeleton, inhibits (both in vitro and in vivo) the shedding of
gp330 immune complexes and the formation of immune depos-
its in passive Heymann nephritis respectively [69, 70].
Immune deposits in tubular basement membranes in active
Heymann nephritis. A few weeks after immunization with
FxlA antigen and coinciding with the onset of proteinuria,
anti-Fx 1 A autologous antibodies leak through damaged glomer-
uli and are exposed to their antigens on the brush border of
proximal tubules. This leakage results in a complement-inde-
pendent, transient damage to the proximal tubules, which
includes the loss of microvilli and a flattening of cells [711. We
also found that gp330 is no longer expressed with restricted
polarity on the luminal side of the tubular epithelial cells under
these circumstances, but also appears basolaterally and in
particular on the basal surface of the tubular cells, facing the
tubular basement membrane (Kerjaschki D, Noble B, Andres
GA, unpublished data). Immunoelectron microscopy has re-
vealed that immune deposits on the tubular basement mem-
brane are located within the coated pits of the modified tubular
epithelial cells (Fig. 10); this finding suggests a mechanism
similar to that of the formation of the glomerular immune
deposits in Heymann nephritis [10]. Within a few weeks after
the proximal tubules become distorted, the morphology of their
epithelial cells is fully restored to normal. It therefore appears
that the molecular mechanisms responsible for the loss of
polarity have been reversed. These mechanisms are not under-
stood, however.
Conclusions and outlook
The formation of immune deposits in Heymann nephritis is a
complex process about which several—but not all—steps are
understood. The currently known facts about this process can
be summarized as follows (Fig. 11): Anti-gp330 antibodies
traverse the glomerular basement membrane to form immune
complexes in the coated pits of glomerular epithelial cells,
where gp330 is exposed. Specific "pathogenic epitopes" of
gp330 must be recognized by these antibodies to initiate the
formation of immune complexes. This phase is followed by
anchoring of the gp330 immune complexes to the GBM, and
detachment from the surface of the podocyte cell membrane.
The glomerular epithelial cells respond by increasing the rate of
synthesis of gp330. Vesicular transport of these new molecules
of gp330 exposes them in the membranes of coated pits adjacent
to immune deposits. By repeated cycles of this process, more
immune complexes can accumulate at the same spot, and
eventually the immune deposits become morphologically appar-
ent. Theoretically, several strategies could be designed to
interrupt this chain of events and halt the disease, for example,
the provision of synthetic antigen decoys that would compete
for the binding of antibodies to "pathogenic epitopes."
It remains to be seen, however, what aspects of this chain of
events are present in human membranous nephropathy. There
is a gp330-related glycoprotein present in human proximal
tubules, but we have shown that it is absent from normal
glomeruli, and it is not detectable in immune deposits in renal
biopsies from patients with membranous nephropathy [72].
Several attempts by others have found some similarities be-
tween Heymann nephritis and individual cases of membranous
nephropathy [73—771, but at the molecular level none of the
pathogenic antigen(s) has emerged [77]. These data raise the
unsettling possibility that the euphemistic term "idiopathic"
will remain with us for the majority of cases of membranous
nephropathy, such as the one presented here. Further study is
required to establish whether a single antigen provides the
target for all cases of human membranous nephropathy or
whether different antigens are involved in different circum-
stances. Clearly, demonstrating the relevance, or lack thereof,
of the findings obtained in experimental Heymann nephritis to
human disease is pressing because, after all, understanding and
treating the human disease remains the ultimate goal and
justification for studying animal model systems.
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Fig. 10. Damaged proximal tubule epithelial cells of a proteinuric rat with active Heymann nephritis (tissue supplied by Dr. G. A. Andres).
Co-localization of gp330 with a monospecific rabbit antibody (indicated by immunoperoxidase reaction product) and endogenous rat IgG (indicated
by gold particles). A, B, C In the apical domains of this slightly distorted tubular epithelial cell, gp330 is seen in association with clathrin-coated
inter-microvillar membrane domains, some of which are extended in areas of loss of tubules. Note that gold particles (denoting rat IgG) co-localize
with gp330 indicating that gp330 immune complexes are formed there. Small clusters of gp330-immune complexes are either floating between
microvilli or are attached to their surface; gp330-immune complexes likely are shed and dispatched into the lumen. D, E Clathrin-coated pits
containing gp330-immune complexes are found on the basal side of proximal tubule cell facing the tubular basement membrane; the strict polarized
apical expression of gp330 is disturbed. These figures suggest that the immune deposits, which appear in the tubular basement membrane, are
caused by a mechanism similar to that operating in the glomerulus. (A, B, C and E x 48,000; D x 75,000.)
Questions and answers basement membrane be expected to pose a greater barrier to
DR. JORDAN J. COHEN (Dean, School of Medicine, State large antibody molecules?
University of New York, Stony Brook, New York): You noted DR. KERJASCHKI: From Heymann nephritis and several other
that pathogenic antibodies have to traverse the basement mem- examples, it appears that there is not an "all or nothing"
brane to get to the site of antigen expression. Wouldn't normal filtration barrier in the glomerulus. Although the site of the
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Fig. 11. Summary of the early events of the formation of an immune deposit in passive Heymann nephritis. A Circulating anti-gp330 IgG ('i')
penetrates the GBM and approaches gp330 (f), a resident membrane glycoprotein of clathrin-coated pits located at the base of the epithelial foot
processes. B Anti-gp330 IgG binds to its antigen gp330, presumably via a limited number of pathogenic epitopes" in the coated pits, forming an
initial immune complex. C The initial immune complex becomes attached to the GBM as early as 15 minutes after injection of the antibody, and
is shed but remains in contact with the coated pit. D The immune deposit grows in size by repeated cycles of in-situ immune complex formation
and shedding into the lamina rara externa until it eventually encroaches on the area of the slit diaphragm. The same result can be obtained if the
immune deposit is fixed to one side of the GBM and the foot processes subsequently moved over the immune deposit until positioned under the
slit diaphragm. The continued growth of immune deposits appears to require the de-novo synthesis by the podocyte of new molecules of gp330
which, like other membrane proteins, are assumed to be delivered via vesicles that eventually fuse with the cell membrane at the base of the foot
processes. (, clathrin coat; ?, gp330: Y, anti-gp330 IgG).
barrier in the lamina rara interna has been clearly shown for
several molecules, such as dextrans, albumin, and endogenous
IgG [78], at least some IgG molecules must penetrate the
basement membrane to generate immune deposits on the sur-
face of the glomerular epithelial cells in Heymann nephritis.
One could speculate that antibodies or other molecules that
interact with components of the basement membrane could
penetrate deeper, but no good experimental proof exists to
support this speculation. In active Heymann nephritis, Jeraj et
al found an antibody system that also interacted with endothe-
hal cells [79]. These researchers speculated that the accessibil-
ity of the glomerular epithelial antigens could be enhanced by
functional modifications of the endothelial cells [79], I must
emphasize though that these thoughts all are speculations that
are not based on firm data at this point.
DR. LEENDERT A. VAN Es (Professor of Medicine, Depart-
ment of Nephrology, Leiden University Hospital, Leiden, The
Netherlands): To what extent do eluates from membranous
nephropathy in humans follow the behavior of eluates from rats
with Heymann nephritis? Do the eluates stain the brush border
of proximal tubules, and do they stain coated pits?
DR. KERJASCHKI: The literature contains several reports of
experiments in which people have used, for example, eluates
from renal cryostat sections from children who had developed
de novo membranous nephropathy in a transplanted kidney.
These eluates stained the proximal tubular brush border [80].
Molecular analysis, however, has not been conducted.
DR. ANDREW REES (Professor of Nephrology, Royal Post-
graduate Medical School, London, United Kingdom): You
showed that complexes in Heymann nephritis are tightly bound
to the GBM, and that gp330 is even more tightly bound than the
IgG. Can you tell us anything about the nature of the bonds
involved and specifically whether complement is involved?
DR. KERJASCHKI: We have tried to break this interaction by
several treatments, such as exposure to detergents, to high- and
low-ionic-strength washes, and to urea. None of these manip-
ulations has successfully extracted components of the immune
deposits from isolated GBMs. In a very acidic or alkaline
milieu, we can extract a major part of the IgG from the immune
deposits in isolated GBMs; however, it appears that the gp330
component stays behind. Taken together, these results suggest
that we are not dealing with an ionic or hydrophobic interac-
tion. It may well be that in the immune complexes the gp330
molecules somehow covalently bind to currently unknown
components of the glomerular basement membrane [59].
The second part of your question is easy to answer. No,
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complement is not involved at all. When we injected purified
gp330 antibodies into experimental animals and looked at renal
tissue after 15 minutes, we found sticking of immune complexes
to the GBM but not a trace of complement.
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): In
various vesicular systems coated with clathrin, H ATPase
pumps appear to play a critical role in the function of the vesicle
by acidification of its interior [81]. You mentioned that in the
proximal tubule, gp330 co-localizes exclusively in the clathrin-
coated intermicrovillar domain of the brush-border membranes.
My understanding is that it has been a matter of dispute whether
H ATPase pumps reside in this particular clathrin-coated
domain. Could you please address this point?
DR. KERJASCHKJ: We don't know whether there are hydrogen
pumps in the proximal tubular brush border that are of rele-
vance to the gp330 molecule. When it comes to the gp330
molecule itself, there appear to be no homologies to any of the
known ionic pumps. My educated guess is that gp330 will turn
out to be a receptor molecule.
DR. MICHEL MIHATSCH (Chairman, Department of Pathol-
ogy, University of Basel, Base!, Switzerland): Heymann nephri-
tis is one model of membranous nephritis, but other models
exist, for example, nephritis induced by injection of cationic
compounds. Is gp330 involved in the pathogenesis of this latter
model? Are there other endogenous proteins involved in rats or
other species? Are there different types of gp330 in different rat
species, and is gp330 cationic? If this is so, then there would be
only one pathogenetic mechanism.
DR. KERJASCHKI: We have to separate the models for
epimembranous glomerulonephritis into two groups: In the first
group, endogenous antigens are present in the glomerulus of
normal animals as antigenic targets. Currently we only have
two examples: the gp330 system and the DPP IV system in the
mouse. There is a possibility, as Dr. Verroust mentioned in a
previous Nephrology Forum, of getting immune deposits from
DPP IV antibodies in the rat [11]. They are, however, very
transient and disappear within a few days, unless you create a
situation in which the animal has time to develop an immune
response against the anti-DPP IV IgG that has been injected. In
this situation, the DPP IV immune complexes behave like
implanted antigens.
In the second group, experimental lesions are caused only by
injection of both heavily cationic compounds and a second
round of antibodies directed against them. We have tried to
localize gp330—for example, in immune deposits induced by
injection of cationic ferritin followed by anti-ferritin antibod-
ies—to answer the question whether the cationic immune
complexes are associated with gp330. The answer is that we did
not find co-localization. Thus, the mechanism by which cationic
compounds stick primarily to the GBM and are subsequently
cross-linked by antibodies might be profoundly different from
that of gp330, in which an endogenous glomerular antigen is the
target of the autoimmunity. To answer your third question, we
do not know whether different gp330 species exist (as a result of
different gene splicing mechanisms) in different rat strains.
DR. MICHEL GOLDMAN (Head, Department of Immunology,
Hôpital Erasme, Université Libre de Bruxelles, Brussels, Be!-
gium): Could you elaborate on the genetic susceptibility to
membranous nephropathy? More precisely, do you know
whether the genetic background in the rat influences the anti-
body response to gp330 in terms of recognition of pathogenic
epitopes?
DR. KERJASCHKI: A very interesting system in which immune
deposits are formed was described by Thoenes et al [82]. They
transplanted kidneys of Lewis rats into Brown-Norway rats.
These two strains were identical in their major histocompatibil-
ity antigen and were different only in the minor histocompati-
bility group. The implanted kidneys from the Lewis rats devel-
oped immune deposits, but the kidneys in the Brown-Norway
rat recipients did not show any immune deposits. In preliminary
experiments in cooperation with Dr. Thoene's group in Munich,
we have found that the IgG eluted from the diseased kidney of
the donor is specific for gp330. It could be possible that we are
looking at two genetically different versions of gp330 in the two
rat strains with different epitope structures.
DR. GOLDMAN: Do you know whether the gp330 antigen is
involved in membranous nephropathy induced experimentally
by chemicals such as mercuric chloride or D-penicillamine?
DR. KERJASCHKI: No.
DR. PIERRE VERROUST (Directeur de Recherche, INSERM,
Hôpita! Tenon, Paris, France): Could you comment on the
mechanisms involved in the induction of proteinuria beyond the
formation of gp330-anti-gp330 immune complexes?
DR. KERJASCHKI: It is clear that significant proteinuria does
not develop in Heymann nephritis without the activation of
complement. As I have indicated, the gp330 antibodies by
themselves appear to be very inefficient at activating the
complement system, or are not able to do so at all, so one of the
things we are very interested in is finding out whether a second
ancillary complement-activating system exists and defining the
antigen(s) involved.
DR. JOHN DONOHOE (Consultant Nephrolo gist, Department
of Nephrology, Beaumont Hospital, Dublin, Ireland): What
implications do your elegant localization studies have for the
natural history of membranous nephropathy? Do they indicate
how relatively crude interventions such as the administration of
steroids and cyclophosphamide occasionally can be beneficial
and on other occasions not so?
DR. KERJASCHKI: The major problem, of course, is that what
I have said so far applies only to rats with Heymann nephritis.
So far, no one has found a good bridge between the rat and the
human. As long as we don't have a catalogue of the molecules
serving as antigens in humans, all statements regarding this
issue will be speculative.
DR. MADIAS: In rare patients with idiopathic membranous
glomerulopathy, anti-GBM disease has developed without pul-
monary manifestations. Is there a comparable analogue in rat
Heymann nephritis? Can you speculate on the pathogenesis of
this evolution?
DR. KERJASCHKI: When Fx1A is used for immunization of
rats, the possibility for the development of anti-GBM disease
theoretically exists, although I am not aware that such devel-
opment actually has been detected. FxIA is a preparation that
varies from one batch to the next and from one laboratory to the
other. If the glomeruli from the renal cortex aren't sieved out
before homogenization, an overlapping syndrome of both anti-
GBM disease and Heymann nephritis might be produced.
DR. COHEN: Given the site of origin of the original antigen in
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Heymann nephritis, why isn't there more florid tubular mani-
festation of the disease?
DR. KERJASCHKI: I'm not sure. There is a tubular manifesta-
tion that appears early in the course of the disease, but as I
mentioned, it is transient.
DR. BRUNO BAGGIO (Associate Professor of Nephrology,
Division of Nephrology, Institute of Internal Medicine, Pa-
dova, Italy): What are the effects of immune complex formation
on glomerular glycosaminoglycan metabolism and on the gb-
merular electrical charge density?
DR. KERJASCHKI: In the case of Heymann nephritis, several
people have studied the distribution of anionic charges using
different cationic probes that can be seen in the electron
microscope. The immune deposits appear to be surrounded by
a halo of glycosaminoglycans. The basement membrane outside
the immune deposits appears undisturbed 183].
DR. JUDIT NAGY (Associate Professor of Medicine, Sec.
Department of Medicine, University Medical School, Pecs,
Hungary): Is the kidney the only organ in the rat that has the
gp330 antigen? When you inject antibody against gp330, do you
see binding and formation of immune deposits in any other
organ?
DR. KEIUAscHKI: No, gp330 is expressed in several types of
epithelial cells in coated pits facing their luminal side. Examples
are epididymis, yolk sac, and type-Il pneumocytes. Extracts of
these organs also have been used for immunization, and gb-
merular immune deposits were obtained. However, extracts
from several other organs that do not contain gp330 were found
inefficient.
The reason why gp330 antibodies are trapped only in the
renal glomerulus after injection may be that this is the only
place in the organism where the antibody has direct access from
the circulation to the antigen gp330. The gp330 is only separated
by fenestrated endothelium and the basement membrane from
the capillary lumina.
DR. VAN Es: You mentioned that in the course of Heymann
nephritis, gp330 is expressed on the basoluminal side. Theoret-
ically, the possibility exists that the proximal tubular epithelial
cell could function as an antigen-presenting cell. Did you look
for the expression of class-I! MHC molecules during the
induction of your model?
DR. KERJASCHKI: No, we have not looked at the expression
of MHC molecules.
DR. REES: Your experiments using the recombinant gp330
fusion proteins are very elegant, but I find them a little
surprising because most antibodies recognize three-dimensional
structures rather than linear sequences of amino acids. Are
there precedents for other systems of autoantibodies to linear
sequences of amino acids?
DR. KERJASCHKI: There are examples of even shorter
stretches than the one we used, such as the N-terminal non-
apeptide of the myelin basic protein, which is a major autoim-
munobogic target in allergic encephalitis [60]. In our case we
assume, since we have purified the C14 fusion protein by
preparative SDS-electrophoresis and electroelution, that the
molecule is badly denaturated and may not refold, but we might
be wrong. We don't know how strong the molecular force is
that drives the molecule into refolding. As a rule of thumb, it is
believed that any peptide that is longer than 12 to 15 amino
acids will no longer have a random coil structure but will start
to fold.
DR. VERROUST: Could you comment on the nature of the
various phases of development of Heymann nephritis?
DR. KERJASCHKI: I believe that after the initial epitope has
been hit by the specific antibody, a mechanism is set into
motion by which more and more epitopes on the gp330 mole-
cule are exposed and are thus accessible for antibodies. This
exposure might stimulate the growth of the immune deposits
dramatically. Evidence for a mechanism like this comes from
previous experiments in which rats with advanced active Hey-
mann nephritis, which was no longer active and contained only
traces of IgG in the immune deposits, were injected with a
monoclonal anti-gp330 IgG, which by itself would not induce
immune deposits. Within a few minutes, the monoclonal IgG
was bound to the "empty" immune deposits. This finding
suggested that the corresponding epitope was left behind in the
old immune deposit, while the IgG was basically cleared out
(unpublished observations). This construction could account
for the rapidity in which relapses of the disease occur in
humans, but this conclusion is, of course, speculative.
DR. ALEX M. DAVISON (Consultant Renal Physician, Depart-
ment of Renal Medicine, St. James's University Hospital,
Leeds, United Kingdom): Human membranous nephropathy
clearly is a complex disease and depends on many factors; for
instance, an antigen seldom produces a uniform response.
Could you speculate on how an understanding of the gp330
system could help in the development of a more rational
therapeutic approach to membranous nephropathy?
DR. KERJASCHKI: Speculations would be somewhat utopic at
this point, but perhaps at least the Heymann nephritis could be
therapeutically manipulated. Assuming you know all the
"pathogenic epitopes" of gp330, one approach would be to
directly interfere with the binding of circulating antibodies, for
example by producing antigenic decoys. Conceptually there are
also other possibilities, for example, interference with the
adhesion of the immune complexes to the GBM, which might
prevent their clearing or—at a distal level—interfering with the
complement-mediated glomerular damage.
DR. CHRISTOPHER G. WINEARLS (Consultant Nephrologist,
Renal Unit, Churchill Hospital, Oxford, United Kingdom): Do
the sera of rats with polyclonal stimulation of the immune
system include antibodies to gp330?
DR. KERJASCHKI: I don't think so, but certain rabbit strains,
when injected with complete adjuvant, started to produce
anti-gp330 antibodies that were able to induce passive Hey-
mann nephritis [84]. The rabbits remain healthy, presumably
because they do not express gp330 in the glomeruli.
DR. GIUSEPPE REMuzzI (Head, Laboratory of Kidney Dis-
ease, Mario Negri Institute, Bergamo, Italy): Because of the
relative frequency of "de novo" membranous nephropathy in
human transplants, I wonder whether gp330 is associated with
the MHC complex? Could you comment on the occurrence of
"de novo" membranous nephropathy in transplant patients
receiving cyclosporine?
DR. KERJASCHKI: First, we do not know any precise relation
between MHC molecules and gp330 at this point. In response to
your second question, we have no clue from Heymann nephri-
tis.
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Addendum
It recently was discovered that the C14-fragment of gp330
shows extensive amino acid sequence homologies to a heparin-
binding membrane protein found in teratocarcinoma cells [85]
as well as to an approximately 40 kD extracellular protein that
is associated with the a2-macroglobulin receptor (which by
amino acid sequencing was shown to be identical to the
LDL-receptor-like protein) [861. Herz et al suggested that the
C 14-domain of gp330 is actually a separate molecule of about 40
kD molecular weight, associated with gp330, but which by itself
belongs to the LDL-receptor family of membrane proteins. By
contrast, several observations indicate that the C 14-domain
could be an indigenous part of the gp330 molecule. These
observations include the finding that in Northern blots of
glomerular RNA, the C14-probe selectively binds to an —10kb
mRNA (which is compatible with a 330 kD protein), while the
same probe binds on cultured mesenchymal cells to a 2.5 kb
mRNA (compatible with a 40 kD protein) (unpublished obser-
vation). Obviously, this conflicting issue will be settled when
the entire amino acid sequence of gp330 has been elucidated.
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